



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



Date: 19 May 2025

To BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001	To National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051
Security Code: 540596	Symbol: ERIS

SUBJECT: REVISION IN OUTCOME OF THE BOARD MEETING HELD TODAY, i.e., MAY 19, 2025

REF: OUTCOME OF THE BOARD MEETING

Dear Sir/Madam,

This has reference to the captioned subject and the consolidated financial results of the Company for the quarter and year ended on March 31, 2025, as approved by the Board of Directors which are now being resubmitted.

The previous submission had one of the rows (Non-Current Assets - Capital work in progress) inadvertently hidden while printing and hence the need for this resubmission.

We would like to clarify that the said error does not affect our profits, financial results, total equity, or total assets for the quarter and year ended March 31, 2025.

This is for your information and record.

Thanking You,

For Eris Lifesciences Limited

Milind Talegaonkar
Company Secretary & Compliance Officer
Membership No: A26493

Registered & Corporate Office:

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867

**INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL CONSOLIDATED
FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF
ERIS LIFESCIENCES LIMITED**

Opinion and Conclusion

We have (a) audited the Consolidated Financial Results for the year ended March 31, 2025 and (b) reviewed the Consolidated Financial Results for the quarter ended March 31, 2025 (refer 'Other Matters' section below), which were subject to limited review by us, both included in the accompanying "Statement of Consolidated Financial Results for the Quarter and Year Ended March 31, 2025 of **ERIS LIFESCIENCES LIMITED** (the "Parent Company") and its subsidiaries (the Parent Company and its subsidiaries together referred to as the "Group"), and its share of the net profit after tax and other comprehensive income of its joint venture for the quarter and year ended March 31, 2025 (the "Statement"), being submitted by the Parent Company pursuant to the requirements of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "LODR Regulations").

(a) Opinion on Annual Consolidated Financial Results

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the audit reports of other auditor on separate financial statements of subsidiaries referred to in Other Matters section below, the Consolidated Financial Results for the year ended March 31, 2025:

(i) includes the financial results of the following entities:

- Eris Lifesciences Limited (Parent)
- Aprica Healthcare Limited (Subsidiary)
- Eris Healthcare Private Limited (Subsidiary)
- Eris Oaknet Healthcare Private Limited (Subsidiary)
- Eris Therapeutics Limited (Subsidiary)
- Eris M.J. Biopharm Private Limited (Subsidiary)
- Eris Pharmaceuticals Limited (Subsidiary)
- Eris Bionxt Private Limited (Subsidiary) (Formerly known as Chemman Labs Private Limited)
- Swiss Parenterals Limited (Subsidiary)
- Levim Lifetech Private Limited (Joint Venture)



- (ii) are presented in accordance with the requirements of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- (iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group for the year ended March 31, 2025.

(b) Conclusion on Unaudited Consolidated Financial Results for the quarter ended March 31, 2025

With respect to the Consolidated Financial Results for the quarter ended March 31, 2025, based on our review conducted and procedures performed as stated in paragraph (b) of Auditor's Responsibilities section below and based on the consideration of the review reports of the other auditors referred to in Other Matters section below, nothing has come to our attention that causes us to believe that the Consolidated Financial Results for the quarter ended March 31, 2025, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Basis for Opinion on the Audited Consolidated Financial Results for the year ended March 31, 2025

We conducted our audit in accordance with the Standards on Auditing ("SA"s) specified under Section 143(10) of the Companies Act, 2013 (the "Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Group and joint venture in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (the "ICAI") together with the ethical requirements that are relevant to our audit of the Consolidated Financial Results for the year ended March 31, 2025 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us and the audit evidence obtained by other auditors in terms of their reports referred to in Other Matters section below is sufficient and appropriate to provide a basis for our audit opinion.

Management's and Board of Directors' Responsibilities for the Statement

This Statement, which includes the Consolidated Financial Results is the responsibility of the Parent Company's Board of Directors and has been approved by them for the issuance. The Consolidated Financial Results for the year ended March 31, 2025, has been compiled from the related audited consolidated financial statements. This responsibility includes the preparation and presentation of the Consolidated Financial Results for the quarter and year ended March 31, 2025 that give a true and fair view of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group including joint venture in accordance with the recognition and measurement principles laid



down in the Indian Accounting Standards, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52 of the LODR Regulations.

The respective Board of Directors of the companies included in the Group and of its joint venture are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and its joint venture and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the respective financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of this Consolidated Financial Results by the Directors of the Parent Company, as aforesaid.

In preparing the Consolidated Financial Results, the respective Board of Directors of the companies included in the Group and joint venture are responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate their respective entities or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and of its joint venture are responsible for overseeing the financial reporting process of the Group and of its joint venture.

Auditor's Responsibilities

(a) Audit of the Consolidated Financial Results for the year ended March 31, 2025

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results for the year ended March 31, 2025 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance; but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Consolidated Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one



resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 and Regulation 52 of the LODR Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its joint venture to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its joint venture to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Consolidated Financial Results, including the disclosures, and whether the Annual Consolidated Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Perform procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the LODR Regulations to the extent applicable.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Results of the entities within the Group and its joint venture to express an opinion on the Annual Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Annual Consolidated Financial Results of which we are the independent auditors. For the other entities included in the Annual Consolidated Financial Results, which have been audited by the other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the Annual Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Consolidated Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Consolidated Financial Results.



We communicate with those charged with governance of the Parent Company and such other entities included in the Consolidated Financial Results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

(b) Review of the Consolidated Financial Results for the quarter ended March 31, 2025

We conducted our review of the Consolidated Financial Results for the quarter ended March 31, 2025 in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

The Statement includes the results of the entities as listed under paragraph (a)(i) of Opinion and Conclusion section above.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

Other Matters

- The Statement includes the results for the quarter ended March 31, 2025 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us. Our report is not modified in respect of this matter.
- We did not audit the financial statements of seven subsidiaries included in the consolidated financial results, whose financial statements reflect total assets of Rs. 2,460.77 Crore as at March 31, 2025 and total revenues of Rs. 423.28 Crore and Rs. 1,406.16 Crore for the quarter and year ended March 31, 2025 respectively, total net profit after tax of Rs. 108.06 Crore and Rs. 379.02 Crore for the quarter and year ended March 31, 2025 respectively and other comprehensive income of Rs. 107.70 Crore and Rs. 378.57 Crore for the quarter and year ended March 31, 2025 respectively and net cash flows of Rs. 71.88 Crore for the year ended March 31, 2025, as considered in the Statement.



Our report on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditor.

- The consolidated financial results also includes the Group's share of profit after tax of Rs. 0.06 Crore and Rs. 0.06 Crore for the quarter and year ended March 31, 2025 respectively and other comprehensive income of Rs. Nil and Rs. Nil for the quarter and year ended March 31, 2025 respectively , as considered in the Statement, in respect of joint venture, whose financial information have not been audited by us. These financial information are unaudited and have been furnished to us by the Management and our opinion and conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these joint venture, is based solely on such unaudited financial information. In our opinion and according to the information and explanations given to us by the Board of Directors, these financial information are not material to the Group.

Our report on the Statement is not modified in respect of the above matter with respect to our reliance on the financial information certified by the Board of the Directors.

For DELOITTE HASKINS & SELLS LLP
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

H.S. Sutaria

Hardik Sutaria
Partner
(Membership No.116642)
(UDIN: 25116642BMLMWW1371)

Place: Ahmedabad
Date: May 19, 2025





Statement of Consolidated Financial results for the quarter and year ended March 31, 2025

Particulars	[Rs in Crore except per share data]				
	For Quarter Ended			For Year Ended	For Year Ended
	March 31, 2025 (Refer note 7)	December 31, 2024 (Unaudited)	March 31, 2024 (Refer note 7 & 12)	March 31, 2025 (Audited)	March 31, 2024 (Audited) (Refer note 12)
Revenue from Operations					
Sale of products	702.60	722.12	547.27	2,879.26	1,991.30
Other operating income	2.70	5.33	3.66	14.38	17.85
Total Revenue from Operations	705.30	727.45	550.93	2,893.64	2,009.15
Other Income	7.95	4.22	15.15	18.36	23.82
Total Income	713.25	731.67	566.08	2,912.00	2,032.97
Expenses					
Cost of materials consumed	68.28	69.43	51.17	276.34	177.81
Purchase of stock-in-trade	95.98	133.22	58.51	473.12	201.52
Changes in inventories of finished goods, work-in-progress and stock-in-trade	5.99	(25.77)	8.50	(35.47)	0.72
Employee benefits expense	121.45	125.39	102.48	505.09	403.82
Finance Costs	54.28	57.17	33.03	231.29	84.80
Depreciation and amortisation expense	77.25	81.00	53.80	315.46	182.51
Other expenses	161.21	174.87	181.84	657.36	550.45
Total Expenses	584.44	615.31	489.34	2,423.19	1,601.63
Profit before share of profit/(loss) from investment in joint venture and tax	128.81	116.36	76.75	488.81	431.34
Share of (profit)/ loss from investment in joint venture, net of tax	(0.06)	-	-	(0.06)	-
Profit before tax	128.87	116.36	76.75	488.87	431.34
Tax Expense					
Current Tax	31.39	24.86	15.73	111.84	82.22
Deferred Tax	(4.87)	4.44	(18.68)	2.36	(48.00)
Total Tax Expense	26.52	29.30	(2.95)	114.20	34.22
Net Profit for the period / year	102.35	87.06	79.70	374.67	397.12
Attributable to :					
- Owners of the Company	93.84	83.76	71.03	351.84	392.05
- Non controlling interest	8.51	3.30	8.67	22.83	5.07
Other Comprehensive Income	(1.95)	(0.39)	(0.41)	(3.29)	(3.05)
Items that will not be reclassified to profit or loss	(1.62)	(0.57)	(0.76)	(3.63)	(4.61)
Income tax relating to items that will not be reclassified to profit or loss	(0.33)	0.18	0.34	0.34	1.56
Total Comprehensive Income	100.40	86.67	79.29	371.38	394.07
Attributable to :					
- Owners of the Company	92.01	83.38	70.62	348.66	389.00
- Non controlling interest	8.40	3.29	8.67	22.72	5.07
Paid Up Equity Share Capital (Face Value of Rs 1 each)	13.62	13.61	13.60	13.62	13.60
Other Equity				2,840.74	2,572.58
Earnings Per Share (of Rs 1 each) (not annualised) :					
Basic	6.90	6.16	5.22	25.85	28.82
Diluted	6.89	6.15	5.21	25.81	28.79

See accompanying notes to the consolidated financial results



Registered & Corporate Office:

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867

1. Statement of Consolidated Assets and Liabilities

(Rs in Crore)


Particulars	As at	As at
	March 31, 2025(Audited)	March 31, 2024(Audited) (Refer note 12)
I. ASSETS :		
(1) Non Current Assets		
(a) Property, Plant and Equipment	604.89	490.87
(b) Right-of-use asset	57.18	48.38
(c) Capital Work in progress	66.74	19.06
(d) Goodwill	911.97	867.17
(e) Other Intangible assets	3,732.44	2,912.74
(f) Intangible assets under development	0.27	0.61
(g) Investments accounted for using the equity method	51.49	-
(h) Financial assets		
Investments	10.51	15.55
Loans	1.08	1.04
Other financial asset	10.81	9.33
(j) Income tax assets (net)	39.54	48.95
(k) Deferred tax assets (net)	289.04	306.95
(l) Other non-current assets	34.22	17.77
Total Non Current Assets	5,810.18	4,738.42
(2) Current Assets		
(a) Inventories	334.83	189.03
(b) Financial assets		
Investments	5.00	-
Trade receivables	458.64	422.00
Cash and cash equivalents	199.74	94.25
Other bank balances	23.09	1,306.39
Loans	5.77	5.56
Other financial asset	3.19	2.22
(c) Other current assets	192.73	282.59
Total Current Assets	1,222.99	2,302.04
TOTAL- ASSETS	7,033.17	7,040.46
II. EQUITY AND LIABILITIES :		
(1) Equity		
(a) Share capital	13.62	13.60
(b) Other Equity	2,840.74	2,572.58
Equity attributable to the owners of the company	2,854.36	2,586.18
(c) Non-controlling interest	417.40	635.91
Total Equity	3,271.76	3,222.09
(2) Non Current Liabilities		
(a) Financial Liabilities		
Borrowings	1,737.51	654.51
Lease Liabilities	44.21	37.02
Other financial liabilities	6.40	6.28
(b) Long-term provisions	68.98	52.72
(c) Other non-current liabilities	4.47	1.38
(d) Deferred tax liabilities (net)	518.45	534.39
Total Non Current Liabilities	2,380.02	1,286.30
(3) Current Liabilities		
(a) Financial Liabilities		
Borrowings	684.15	2,080.76
Lease Liabilities	12.05	8.98
Trade payables		
A) Due to Micro and Small Enterprises	15.98	26.59
B) Due to other than Micro and Small Enterprises	316.37	192.34
Other financial liabilities	165.14	72.79
(b) Short-term provisions	78.09	62.05
(c) Other current liabilities	66.00	48.96
(d) Income tax liabilities (net)	43.61	39.59
Total Current Liabilities	1,381.39	2,532.07
Total Liabilities	3,761.41	3,818.37
TOTAL- EQUITY AND LIABILITIES	7,033.17	7,040.46



2. Statement of Consolidated Cash Flows for the year ended March 31, 2025

(Rs in Crore)

	For the year ended March 31, 2025 (Audited)	For the year ended March 31, 2024 (Audited) (Refer note 12)
A. Cash flow from operating activities		
Profit before tax	488.87	431.34
Adjustments for :		
Depreciation and amortisation expense	315.46	182.51
Net Loss on property plant and equipment sold / written off/ Early termination of lease	0.92	2.14
Finance costs	231.29	84.80
Acquisition expense for investment in subsidiary	-	0.80
Interest income	(5.06)	(7.01)
Share of profit of an joint venture, net of tax	(0.06)	-
Exceptional items	-	-
Deferred Capital Subsidy	(0.63)	(0.45)
Net gain on sale of investments carried at fair value through profit or loss	(3.00)	(5.53)
Net MTM gain on investments carried at fair value through profit or loss	-	(3.85)
Share based payment expense	9.13	0.75
Operating profit before working capital changes	1,036.92	685.51
Changes in working capital:		
Adjustments for (increase) / decrease in operating assets:		
Trade receivables	(9.11)	(57.09)
Inventories	(94.36)	(16.94)
Other assets	119.46	(16.22)
Adjustments for increase / (decrease) in operating liabilities:		
Trade Payables	67.94	90.98
Financial Liabilities	0.99	(73.44)
Provisions	24.27	(3.59)
Other Liabilities	16.78	(22.44)
Cash generated from operations	1,162.89	586.77
Net income tax paid	(97.88)	(100.75)
Net cash generated from operating activities (A)	1,065.01	486.01
B. Cash flow from investing activities		
Purchase of property, plant and equipment (including intangible assets, CWIP and Capital Advance)	(155.00)	(129.16)
Proceeds from sale of property plant and equipment	0.37	-
Receipt of government grants	3.88	-
Consideration paid towards investment in Joint venture	(51.43)	-
Consideration paid towards business combination (including transaction costs)	(1,169.00)	(566.80)
Investments in mutual funds and fixed deposit	-	17.88
Proceeds from redemption of mutual funds and fixed deposit	3.00	30.53
Loan given	(0.25)	(1.65)
(Investment in) / proceeds of Bank balances not considered as cash and cash equivalents	1,284.03	(1,212.31)
Interest received	4.43	6.99
Net cash used in investing activities (B)	(79.97)	(1,854.52)
C. Cash flow from financing activities		
Proceeds from borrowings	1,436.44	1,623.10
Repayment of borrowings	(1,833.65)	(159.40)
Interest Paid	(145.06)	(77.30)
Principal element to lease payment	(8.72)	(0.89)
Proceeds from issue of equity share capital (Employee stock options plan)	7.22	4.54
Payment towards acquisition of the Non-controlling interest	(237.50)	(10.28)
Dividend paid	(100.05)	(0.00)
Net cash (used in) / generated from financing activities (C)	(881.32)	1,379.78
Net increase/(decrease) in cash and cash equivalents (A+B+C)	103.72	11.27
Cash and cash equivalents at the beginning of the year	94.25	56.02
Cash and cash equivalents acquired pursuant to business acquisition	1.77	26.96
Cash and cash equivalents at end of the year	199.74	94.25




3. Additional information pursuant to Regulation 52(4) of Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015 as amended for the quarter and year ended March 31, 2025

Particulars	Numerator	Denominator	Quarter Ended			Year Ended	Year Ended
			March 31, 2025 (Refer note 7)	December 31, 2024 (Unaudited)	March 31, 2024 (Refer note 7 & 12)	March 31, 2025 (Audited)	March 31, 2024 (Audited) (Refer note 12)
Debt – Equity Ratio	Total Debt (including lease liabilities)	Total Equity	0.76	0.79	0.86	0.76	0.86
Debt Service Coverage Ratio	Profit after tax+Other income+ Depreciation and amortisation expense+finance Costs+Committed Principal repayments made during the period for long term loans	Finance Costs +Committed Principal repayments made during the period for long term loans	2.36	2.27	2.22	2.24	3.56
Interest service coverage ratio	Earnings before Interest and Tax	Finance Costs	3.37	3.03	3.32	3.11	6.09
Outstanding redeemable preference shares (quantity and value)			NIL	NIL	NIL	NIL	NIL
Capital redemption reserve/debenture redemption reserve (Rs in crore)			0.17	0.17	0.17	0.17	0.17
Net worth (Rs in crore)			3,271.76	3,267.09	3,222.09	3,271.76	3,222.09
Net profit after tax (Rs in crore)			102.35	86.93	79.70	374.67	397.12
Earnings per share:			6.90	6.15	5.22	25.85	28.82
Current Ratio	Current Assets	Current Liabilities	0.89	1.03	0.91	0.89	0.91
Long term debt to working capital	Long-term borrowing+Lease liabilities including its current maturity	Current Assets-Current liabilities (excluding current maturity)	14.74	6.71	9.31	14.74	9.31
Bad debts to Account receivable ratio	Bad debts	Trade receivables	NIL	NIL	NIL	NIL	NIL
Current liability ratio	Current liabilities	Total liabilities	0.37	0.34	0.66	0.37	0.66
Total debts to total assets	Total Debt (including lease liabilities)	Total Assets	0.35	0.36	0.39	0.35	0.39
Debtors' turnover	Sales	Debtors	6.28	5.21	4.72	6.28	4.72
Inventory Turnover Ratio	Cost of goods sold	Average Inventory	2.73	2.90	2.37	2.73	2.37
Operating margin percent	Earnings before Interest and Tax	Revenue from Operations	25.96%	23.83%	19.93%	24.89%	25.69%
Net profit margin percent:	Profit after tax	Revenue from Operations	14.51%	11.95%	14.47%	12.95%	19.77%



Notes to financial results

- 4 The above statement of Consolidated Financial Results ("the Statement") of the Company has been recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 19, 2025.
- 5 The Company is primarily engaged in one business segment namely - "Pharmaceuticals" - as determined by the chief operating decision maker in accordance with Ind AS 108 - "Operating Segment".
- 6 The Board of Directors of the Company has declared an interim dividend of Rs 7.35/- (at the rate of 735 Percent) per equity share of the face value of Rs. 1/- each for the financial year 2024-25 at its meeting held on February 07, 2025.
- 7 The figures for the quarter ended March 31, 2025 and quarter ended March 31, 2024 as reported in these financial results are the balancing figures between the Audited figures in respect of the full financial year and the unaudited published year to date figures up to the third quarter of the current and previous financial year which was subject to limited review.
- 8 During the quarter ended March 31, 2025, 33,287 ordinary shares of Rs 1 each were issued and allotted under the Company's Employee Stock Option Scheme 2021. Consequently, the issued and paid-up Share Capital of the Company as on March 31, 2025 stands increased to Rs 13.62 crore.
- 9 The financial results for the current quarter and year ended on March 31, 2025 includes the impact of acquisition of Swiss Parenterals Limited in February 2024, Nephrology and Dermatology business in November 2023 from Biocon Biologicals Limited and Indian Branded Formulations business in April 2024 from Biocon Biologicals Limited. The results of the current quarter and year ended March 31, 2025 are not comparable with those of corresponding periods included in the aforesaid statement due to said acquisitions.
- 10 During the quarter ended September 30, 2024, the Parent Company has acquired 1,43,13,418 equity shares representing 100% of the equity share capital of Eris Bionxt Private Limited (formerly known as Chemman Labs Private Limited) from its erstwhile shareholders for a consideration of Rs. 27 Crores. The transaction achieved closure in October 2024, on completion of all relevant conditions precedent to the transaction. The Parent Company is in the process of making final determination of fair values of identified assets and liabilities for the purpose of Purchase price allocation. Pending this, the business combination has been accounted based on provisional fair valuation report. The results of the current quarter ended March 31, 2025 are not comparable with those of corresponding periods included in the aforesaid statement due to said acquisition.
- 11 Pursuant to Share Purchase agreement and Share Subscription agreement entered on January 10, 2025, and pursuant to deed of assignment dated February 18, 2025, Eris Bionxt Private Limited (formerly known as Chemman Labs Private Limited), a wholly owned subsidiary of the Parent Company, has completed the acquisition of 30% stake for Rs.51.43 Crores of Levim Lifetech Private Limited. The transaction has achieved closure on February 27, 2025.



- 12 During the year ended March 31, 2024, the Group had acquired 51% stake in Swiss Parenterals Limited for a consideration (including acquisition expense) of Rs.637.50 crore. The Group has completed the final determination of fair values of identified assets and liabilities for the purpose of Purchase Price Allocation for the aforesaid acquisitions in the current year. Consequent to above the Group has restated the reported amounts of the previous periods as required by the applicable accounting standards. The summarized position of the reported and restated amounts is as below:

	Quarter ended March 31, 2024		Quarter ended December 31, 2024		Year ended March 31, 2024	
	Reported	Restated	Reported	Restated	Reported	Restated
Profit before tax	76.65	76.75	116.16	116.36	431.24	431.34
Profit after tax	79.63	79.70	86.93	87.06	397.05	397.12
Total Other Comprehensive Income	79.22	79.29	86.54	86.67	394.00	394.07

Consolidated Balance Sheet

	March 31, 2024	
	Reported	Restated
Non Current Assets	4,746.76	4,738.42
Current Assets	2,302.07	2,302.04
Total Assets	7,048.84	7,040.46
Total Equity	3,222.03	3,222.09
Non-current liabilities	1,294.73	1,286.30
Current liabilities	2,532.08	2,532.07
Total Equity and Liabilities	7,048.84	7,040.46

Statement of consolidated cash flows:

	March 31, 2024	
	Reported	Restated
Net cash generated from operating activities	486.01	486.01
Net cash generated from Investing activities	-1,854.52	-1,854.52
Net cash generated from financing activities	1,379.78	1,379.78

For Eris Lifesciences Limited,



[Handwritten Signature]

Amit Bakshi
Chairman and Managing Director
DIN : 01250925

Place: Ahmedabad
Date: May 19, 2025

